BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Plans to Participate in 33rd Annual ROTH Conference, $10M Registered Direct Offering

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its CEO and Chairman, James Sapirstein, will participate in a panel discussion during the ROTH Conference slated to be held virtually from March 15-17, 2021. According to the update, the panel, “Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade Away: A discussion of various developmental therapeutics for SARS-CoV-2 infection,” is scheduled to begin at 12:00 p.m. ET on March 15, 2021. During the panel, Sapirstein will discuss the need for drug therapies to address issues related to COVID-19, including the prevalence of gastrointestinal symptoms in an increasing number of people infected by the virus.

In addition, AzurRx BioPharma announced its entry into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 7,858,548 shares of common stock (or common stock equivalent) and warrants to purchase up to an aggregate of 3,929,274 shares of common stock at an effective purchase price of $1.2725 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants are exercisable immediately, at an exercise price of $1.21 per share, and will expire five years following the date of issuance. Subject to the satisfaction of customary conditions, the closing of the offering is expected to occur on or about March 10, 2021. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

To view the full press releases, visit https://ibn.fm/3RWa3 and https://ibn.fm/tc8Y0

About AzurRx BioPharma Inc.

AzurRx BioPharma is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs in 2021 using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 immune checkpoint inhibitor colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork